BRCA genetic testing of individuals from families with low prevalence of cancer: Experiences of carriers and implications for population screening

Genetics in Medicine

Volumn 14, Issue 7, 2012, Pages 688-694

  Shkedi Rafid, Shiri ^a,b   Gabai Kapara, Efrat ^c,d   Grinshpun Cohen, Julia ^d   Levy Lahad, Ephrat ^c,d  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c HEBREW UNIVERSITY   (Israel)

^d SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

Ashkenazi Jews; BRCA; family history; personal experience; population screening

Indexed keywords

ADULT; ARTICLE; ATTITUDE TO HEALTH; CANCER PREVENTION; CONFUSION; EARLY DIAGNOSIS; ETHNIC GROUP; FAMILY HISTORY; FEMALE; GENETIC SCREENING; HEALTH PROMOTION; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; JEW; MASS SCREENING; MEDICAL HISTORY; NEOPLASM; NORMAL HUMAN; ONCOGENE; PREVALENCE; PSYCHOLOGICAL ASPECT; SEMI STRUCTURED INTERVIEW;

ADULT; ATTITUDE TO HEALTH; BREAST NEOPLASMS; FEMALE; FOUNDER EFFECT; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENETICS, POPULATION; HETEROZYGOTE; HUMANS; JEWS; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS; PREVALENCE; QUESTIONNAIRES; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84863671080     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.2012.31     Document Type: Article

References (40)

1. Whittemore AS, Gong G, John EM, et al. Prevalence of BRCA1 mutation carriers among US non-Hispanic Whites. Cancer Epidemiol Biomarkers Prev 2004;13(12):2078-2083. (Pubitemid 40054301)
2. Whittemore AS, Gong G, Itnyre J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three US population-based case-control studies of ovarian cancer. Am J Hum Genet 1997;60(3):496-504. (Pubitemid 27097597)
3. Ford D, Easton DF, Peto J. Estimates of the gene-frequency of brca1 and its contribution to breast and ovarian-cancer incidence. Am J Hum Genet 1995;57(6):1457-1462.
4. Antoniou AC, Pharoah PD, McMullan G, et al. A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer 2002;86:76-83. (Pubitemid 34146344)
5. Phelan CM, Kwan E, Jack E, et al. A low frequency of non-founder BRCA1 mutations in Ashkenazi Jewish breast-ovarian cancer families. Hum Mutat 2002;20:352-357. (Pubitemid 35285054)
6. Roa BB, Boyd AA, Volcik K, Richards CS. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 1996;14:185-187. (Pubitemid 26338801)
7. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401-1408. (Pubitemid 27208598)
8. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994;343:692-695. (Pubitemid 24087847)
9. Antoniou AC, Pharoah PD, Narod S, et al. Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. J Med Genet 2005;42:602-603. (Pubitemid 40993838)
10. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007;25:1329.
11. Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010;304:967-975.
12. NCCN. National Comprehensive Cancer Network (NCCN) guidelines. http://www.nccn.org. 2011
13. Murff HJ, Spigel DR, Syngal S. Does this patient have a family history of cancer? An evidence-based analysis of the accuracy of family cancer history. JAMA 2004;292:1480.
14. Schiffman SC, Chagpar AB. Does a family history of male breast cancer influence risk perception and use of genetic testing? Am Surg 2010;76: 879-882.
15. Yong MC, Zhou XJ, Lee SC. The importance of paternal family history in hereditary breast cancer is underappreciated by health care professionals. Oncology 2003;64(3):220-226. (Pubitemid 36438806)
16. Culver JO, Edwards QT, MacDonald DJ, Weitzel JN. USPSTF guidelines will miss BRCA families due to paternal inheritance or a truncated family tree. Ann Intern Med 2005.
17. King MC, Marks JH, Mandell JB; New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003;302:643.
18. Weitzel JN, Lagos VI, Cullinane CA, et al. Limited family structure and BRCA gene mutation status in single cases of breast cancer. JAMA 2007;297:2587.
19. Wilson JM, Jungner YG. Principles and practice of mass screening for disease. 1968. Bol Oficina Sanit Panam 1968;65(4): 281-393.
20. Lynch HT, Snyder C, Lynch JF, et al. Patient responses to the disclosure of BRCA mutation tests in hereditary breast-ovarian cancer families. Cancer Genet Cytogenet 2006;165:91-97. (Pubitemid 43343501)
21. Godard B, ten Kate L, Evers-Kiebooms G, Aym S. Population genetic screening programmes: principles, techniques, practices, and policies. Eur J Hum Genet 2003;11(suppl 2):S49-S87. (Pubitemid 38263569)
22. Rubinstein WS, Jiang H, Dellefave L, Rademaker AW. Cost-effectiveness of population-based BRCA1/2 testing and ovarian cancer prevention for Ashkenazi Jews: a call for dialogue. Genet Med 2009;11:629.
23. Metcalfe KA, Poll A, Royer R, et al. Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women. J Clin Oncol 2010;28:387.
24. Metcalfe KA, Poll A, Llacuachaqui M, et al. Patient satisfaction and cancer related distress among unselected Jewish women undergoing genetic testing for BRCA1 and BRCA2. Clin Genet 2010;78(5):411-417.
25. Saunders KH, Nazareth S, Pressman PI. Case report: BRCA in the Ashkenazi population: are current testing guidelines too exclusive? Hered Cancer Clin Pract 2011;9:3.
26. Glaser BG, Strauss AL. Grounded Theory: The Discovery of Grounded Theory. de Gruyter: New York, 1967.
27. Dagan E, Goldblatt H. The twilight zone between health and sickness: a qualitative exploration with asymptomatic BRCA1 and 2 mutation carriers. Women Health 2009;49:263-279.
28. Swirski S, Konor-Attias E. Israel: A Social Report 2003. http://www.adva.org/uploaded/ISRAEL-2003-ENG.pdf.
29. Anido A, Carlson LM, Sherman SL. Attitudes toward fragile X mutation carrier testing from women identified in a general population survey. J Genet Couns 2007;16:97-104. (Pubitemid 46355050)
30. Hamilton R, Williams JK, Skirton H, Bowers BJ. Living with genetic test results for hereditary breast and ovarian cancer. J Nurs Scholarsh 2009;41:276-283.
31. Meijers-Heijboer EJ, Verhoog LC, Brekelmans CT, et al. Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. Lancet 2000;355:2015-2020. (Pubitemid 30339238)
32. van Oostrom I, Meijers-Heijboer H, Lodder LN, et al. Long-term psychological impact of carrying a BRCA1/2 mutation and prophylactic surgery: a 5-year follow-up study. J Clin Oncol 2003;21:3867.
33. Metcalfe KA, Birenbaum-Carmeli D, Lubinski J, et al.; Hereditary Breast Cancer Clinical Study Group. International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer 2008;122:2017-2022. (Pubitemid 351441190)
34. Rosner G, Rosner S, Orr-Urtreger A. Genetic testing in Israel: an overview. Annu Rev Genomics Hum Genet 2009;10:175-192.
35. Mishori Dery A, Carmi R, Shoham Vardi I. Different perceptions and attitudes regarding prenatal testing among service providers and consumers in Israel. Community Genet 2007;10(4):242-251. (Pubitemid 47482084)
36. Remennick L. The quest for the perfect baby: why do Israeli women seek prenatal genetic testing? Sociol Health Illn 2006;28:21-53. (Pubitemid 43332399)
37. Suter SM. The routinization of prenatal testing. Am J Law Med 2002; 28(2-3):233-270.
38. McKinnon WC, Baty BJ, Bennett RL, et al. Predisposition genetic testing for late-onset disorders in adults: a position paper of the National Society of Genetic Counselors. JAMA 1997;278(15):1217.
39. Collins FS, Benjamin LJ, Botstein D, et al.; National Advisory Council for Human Genome Research. Statement on use of DNA testing for presymptomatic identification of cancer risk. JAMA 1994;271(10):785. (Pubitemid 24074528)
40. Prainsack B, Firestine O. Science for survival: biotechnology regulation in Israel. Sci Public Policy 2006;33(1):33-46.